Clinical Trial

Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager

Study acronym: CHUQUL_HO001
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma. They are currently used in cases of refractory multiple myeloma but are also being investigated in earlier lines of treatment. However, these new therapies can lead to deeper immunosuppression and exacerbate an underlying immunosuppressive state in patients with multiple myeloma. As a result, infectious complications are common with these therapies and are a significant concern. Therefore, preventing infections in this population is crucial. However, data on the best strategies for prevention are currently lacking.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-07-28; most recent amendment 2026-07-21.
Status change: Not Yet Recruiting → Recruiting 2026-01-05
Trial Details
NCT Number NCT07094048
Lead Sponsor CHU de Quebec-Universite Laval
Conditions Multiple Myeloma Refractory, Relapsed Multiple Myeloma
Enrollment 80 participants
Start Date 2026-01-05
Primary Completion 2028-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-22